Cyclerion Therapeutics Total Assets Growth & History (CYCN)
Cyclerion Therapeutics's total assets was $10.0M for fiscal 2025.
View full Cyclerion Therapeutics company overviewCyclerion Therapeutics annual total assets history
| Fiscal year | Period ended | Total assets | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $10.0M | $410,000 | +4.28% |
| 2024 | 2024-12-31 | $9.6M | −$3.8M | −28.41% |
| 2023 | 2023-12-31 | $13.4M | −$4.7M | −26.02% |
| 2022 | 2022-12-31 | $18.1M | −$41.3M | −69.53% |
| 2021 | 2021-12-31 | $59.3M | −$56.0M | −48.58% |
| 2020 | 2020-12-31 | $115.4M | −$71.1M | −38.13% |
| 2019 | 2019-12-31 | $186.5M | $179.1M | +2419.63% |
| 2018 | 2018-12-31 | $7.4M | — | — |
Cyclerion Therapeutics quarterly total assets
| Fiscal quarter | Period ended | Total assets | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $6.9M | −$2.4M | −26.04% |
| Q1 2026 | 2026-03-31 | $8.5M | −$1.3M | −13.63% |
| Q4 2025 | 2025-12-31 | $10.0M | $410,000 | +4.28% |
| Q3 2025 | 2025-09-30 | $10.4M | $1.5M | +17.05% |
| Q2 2025 | 2025-06-30 | $9.4M | −$695,000 | −6.91% |
| Q1 2025 | 2025-03-31 | $9.8M | −$1.5M | −13.35% |
| Q4 2024 | 2024-12-31 | $9.6M | −$3.8M | −28.41% |
| Q3 2024 | 2024-09-30 | $8.9M | −$6.3M | −41.51% |
| Q2 2024 | 2024-06-30 | $10.1M | −$32,000 | −0.32% |
| Q1 2024 | 2024-03-31 | $11.4M | −$92,000 | −0.80% |
| Q4 2023 | 2023-12-31 | $13.4M | −$4.7M | −26.02% |
| Q3 2023 | 2023-09-30 | $15.2M | −$9.8M | −39.27% |
| Q2 2023 | 2023-06-30 | $10.1M | −$25.1M | −71.33% |
| Q1 2023 | 2023-03-31 | $11.5M | −$35.1M | −75.38% |
| Q4 2022 | 2022-12-31 | $18.1M | −$41.3M | −69.53% |
| Q3 2022 | 2022-09-30 | $25.1M | −$42.7M | −63.02% |
| Q2 2022 | 2022-06-30 | $35.2M | −$40.5M | −53.50% |
| Q1 2022 | 2022-03-31 | $46.5M | −$53.4M | −53.46% |
| Q4 2021 | 2021-12-31 | $59.3M | −$56.0M | −48.58% |
| Q3 2021 | 2021-09-30 | $67.7M | −$63.7M | −48.45% |
| Q2 2021 | 2021-06-30 | $75.7M | −$52.3M | −40.85% |
| Q1 2021 | 2021-03-31 | $100.0M | −$40.1M | −28.61% |
| Q4 2020 | 2020-12-31 | $115.4M | −$71.1M | −38.13% |
| Q3 2020 | 2020-09-30 | $131.4M | −$78.3M | −37.34% |
| Q2 2020 | 2020-06-30 | $128.0M | −$107.5M | −45.63% |
| Q1 2020 | 2020-03-31 | $140.0M | $130.3M | +1332.83% |
| Q4 2019 | 2019-12-31 | $186.5M | $179.1M | +2419.63% |
| Q3 2019 | 2019-09-30 | $209.7M | — | — |
| Q2 2019 | 2019-06-30 | $235.5M | — | — |
| Q1 2019 | 2019-03-31 | $9.8M | — | — |
| Q4 2018 | 2018-12-31 | $7.4M | — | — |
Cyclerion Therapeutics total assets trends
Over the last five fiscal years, Cyclerion Therapeutics's total assets decreased from $115.4M to $10.0M, a change of −$105.4M. The latest reported quarter, Q2 2026, shows $6.9M.
What total assets mean
Total assets are the resources a company controls at a reporting-period end, including cash, investments, receivables, inventory, property, intangible assets, and other reported assets. The composition of assets differs substantially by industry.
SEC-reported total assets
TickerStat uses total assets reported in company SEC filings. When a filer provides the equivalent balance-sheet total as liabilities and equity, that reported amount is used because total assets must equal total liabilities plus equity. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Cyclerion Therapeutics source filings ↗